AbGn 7

Drug Profile

AbGn 7

Alternative Names: AbGn-7

Latest Information Update: 25 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AbGenomics Corporation
  • Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
  • Mechanism of Action Apoptosis stimulants; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Gastric cancer; Solid tumours

Most Recent Events

  • 31 Jan 2013 AbGenomics completes a phase Ia/b trial in Solid tumours (late-stage disease, second-line therapy or greater) including Gastric cancer (combination therapy, late-stage disease) in USA and Taiwan (NCT01466569)
  • 04 Jun 2012 Phase-I clinical trials in Gastric cancer (combination therapy, late-stage disease) in Taiwan (IV)
  • 04 Jun 2012 Phase-I clinical trials in Solid tumours (combination therapy, late-stage disease) in Taiwan (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top